Phase I trial of etoposide, carboplatin, and GM-CSF in extensive small- cell lung cancer: A Cancer and Leukemia Group B study (CALGB 8832)

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 20, Issue 1, 1997, Pages 24-30

  Luikart, Sharon D ^a,b   Herndon II, James E ^c   Hollis, Donna R ^c   MacDonald, Margaret ^b   Maurer, L Herbert ^d   Crawford, Jeffrey ^e   Clamon, Gerald H ^f   Wright, Jonathan ^g   Perry, Michael C ^h   Ozer, Howard ⁱ   Green, Mark R ^j  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^c CALGB Statistical Center   (United States)

^d NORRIS COTTON CANCER CENTER   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^g SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^h UNIVERSITY OF MISSOURI   (United States)

ⁱ EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UCSD MEDICAL CENTER   (United States)

more..

Author keywords

Carhoplatin; Dose intensity; Etoposide; GM CSF; Molgramostim; Small cell lung cancer

Indexed keywords

CARBOPLATIN; ETOPOSIDE; INTERLEUKIN 6; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; DOSE RESPONSE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG SMALL CELL CANCER; MALE; MAXIMUM PERMISSIBLE DOSE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; RASH; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SMALL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; REMISSION INDUCTION; SURVIVAL ANALYSIS;

EID: 0031014192     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199702000-00006     Document Type: Article

References (29)

1. Smith IE, Evans BD, Gore ME, et al. Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer. J Clin Oncol 1987;5:185-9.
2. Bishop JF, Raghavan D, Stuart-Harris R, et al. Carboplatin (CBDCA, JM8) and VP-16-213 in previously untreated patients with small-cell lung cancer. J Clin Oncol 1987;5:1574-8.
3. Evans WK Eisenhauer E, Hughes P, et al. VP-16 and carboplatin in previously untreated patients with extensive small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group. Br J Cancer 1988;58:464-8.
4. Luikart SD, Goutsou M, Mitchell ED, et al. Phase I/II trial of etoposide and carboplatin in extensive small-cell lung cancer. A report from the Cancer and Leukemia Group B. Am J Clin Oncol 1993;16:127-31.
5. Rowe JM, Rapoport AP. Hemopoietic growth factors: a review. J Clin Pharmacol 1992;32:486-501.
6. Metcalf D. The molecular biology and functions of the granulocyte-macrophage colony-stimulating factors. Blood 1986;67: 257-67.
7. Weisbart RH, Kalena A, Schuh A, et al. GM-CSF induces human neutrophil IgA-mediated phagocytosis by an IgA Fc receptor activation mechanism. Nature 1988;32:647-8.
8. Grabstein KH, Urdal DL, Tushinski RJ, et al. Induction of macrophage tumoricidal activity by GM-CSF. Science 1986;232:506-8.
9. Nemunaitis J, Rabinowe SN, Singer JW, et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991;324:1773-8.
10. De Vries EG, Biesma B, Willemse PHB, et al. A double-blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma. Cancer Res 1991;51:116-22.
11. Grant SM, Heel RC. Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF). Drugs 1992;43:516-60.
12. Edmonson JH, Long HJ, Jeffries JA, et al. Amelioration of chemotherapy-induced thrombocytopenia by GM-CSF apparent dose and schedule dependency. J Natl Cancer Inst 1989;81: 1510-2.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
14. Hollander M, Wolfe DA. Nonparametric statistical methods. New York: John Wiley, 1973.
15. Ihde DC, Mulshine JL, Kramer BS, et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 1994;12:2022-34.
16. Miller AA, Herndon J, Hollis D, et al. Phase III study of 21 day oral versus 3 day iv etoposide (E) in combination with iv cisplatin (C) in extensive small cell lung cancer: a Cancer and Leukemia Group B Study (CALGB 9033) [Abstract]. Proc Am Soc Clin Oncol 1994;13:326.
17. Evans WK, Shepherd FA, Feld R, et al. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol 1985;3:1471-7.
18. Krigel R, Palackdharry CS, Padavic K, et al. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small cell lung cancer. J Clin Oncol 1994;12:1251-8.
19. Moore MJ, Iscoe N, Tannock IF. A phase II study of methotrexate, vinblastine, doxorubicin and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factor in patients with advanced transitional cell carcinoma. J Urol 1993;150:1131-4.
20. Mellstedt H. Induction of anti-granulocyte-macrophage colony-stimulating factor antibodies against exogenous nonglycosylated GM-CSF: biological implications. J Interferon Res 1994;14:179-80.
21. Caracciolo D, Clark SC, Rovera G. Human interleukin-6 supports granulocytic differentiation of hematopoietic progenitor cells and acts synergistically with GM-CSF. Blood 1989;73: 666-70.
22. Ishibashi T, Kimura H, Uchida T. Human interleukin 6 is a direct promoter of maturation of megakaryocytes in vitro. Proc Natl Acad Sci U S A 1989;86:5953-7.
23. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-56.
24. Brandt SJ, Peters WP, Atwater SK, et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 1988;318:869-76.
25. Potter MN, Mott MG, Oakhill A. Granulocyte-macrophage colony-stimulating factor (GM-CSF), hypocalcemia, and hypomagnesemia. Ann Intern Med 1990;112:715.
26. Edmonson JH, Hartmann LC, Long HL, et al. Granulocyte-macrophage colony-stimulating factor. Cancer 1992;70:2529-39.
27. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N Engl J Med 1992;327:28-35.
28. Baldwin GC, Gasson JC, Kaufman SE, et al. Nonhematopoietic tumor cells express functional GM-CSF receptors. Blood 1989;73:1033-7.
29. Pedrazzoli P, Bacciocchi G, Bergamaschi G, et al. Effects of granulocyte-macrophage colony-stimulating factor and interleukin-3 on small cell lung cancer cells. Cancer Invest 1994;12:283-8.